Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous system lymphoma, a rare and aggressive lymphoma of the brain and spinal cord. The change is expected to expand access to commercial CAR T-cell therapy for eligible patients with relapsed or refractory disease.
Continue Reading this article here
